Estimated restructuring charges 0.02 0.02
Estimated amortization expense 0.07 0.07
Adjusted results $0.15 $0.20
An explanation of the ways in which Boston Scientific management uses
these non-GAAP measures to evaluate its business, the substance behind
Boston Scientific management's decision to use these non-GAAP measures,
the material limitations associated with the use of these non-GAAP
measures, the manner in which Boston Scientific management compensates for
those limitations, and the substantive reasons why Boston Scientific
management believes that these non-GAAP measures provide useful
information to investors is included in the exhibit labeled "Use of Non-
GAAP Financial Measures.
Use of Non-GAAP Financial Measures
To supplement Boston Scientific's consolidated condensed financial
statements presented on a GAAP basis; the Company discloses certain non-
GAAP measures that exclude certain amounts, including non-GAAP net income,
non-GAAP net income per diluted share, and regional and divisional revenue
growth rates that exclude the impact of foreign exchange. These non-GAAP
measures are not in accordance with, or an alternative for, generally
accepted accounting principles in the United States.
The GAAP measure most comparable to non-GAAP net income is GAAP net income
and the GAAP measure most comparable to non-GAAP net income per diluted
share is GAAP net income per diluted share. Reconciliations of each of
these non-GAAP financial measures to the corresponding GAAP measure are
included in the accompanying schedules.
To calculate regional and divisional revenue growth rates that exclude the
impact of foreign exchange, the Company converts actual current-period net
sales from local
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved